BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20125118)

  • 1. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance.
    Reed K; Hembruff SL; Sprowl JA; Parissenti AM
    Pharmacogenomics J; 2010 Dec; 10(6):489-504. PubMed ID: 20125118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
    El-Khoury V; Breuzard G; Fourré N; Dufer J
    Br J Cancer; 2007 Aug; 97(4):562-73. PubMed ID: 17667922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of promoter methylation of mdr-1 gene and histone acetylation status with multidrug resistance in MCF-7/Adr cells.
    Huang C; Cao P; Xie Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 May; 34(5):369-74. PubMed ID: 19483282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accurate monitoring of promoter gene methylation with high-resolution melting polymerase chain reaction using the ABCB1 gene as a model.
    Mencalha AL; Rodrigues EF; Abdelhay E; Fernandez TS
    Genet Mol Res; 2013 Mar; 12(1):714-22. PubMed ID: 23546954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
    Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
    Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
    Spitzwieser M; Pirker C; Koblmüller B; Pfeiler G; Hacker S; Berger W; Heffeter P; Cichna-Markl M
    Oncotarget; 2016 Nov; 7(45):73347-73369. PubMed ID: 27689338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the ABCB1 downstream gene promoter accompanies ABCB1 gene amplification and increased expression in docetaxel-resistant MCF-7 breast tumor cells.
    Reed K; Hembruff SL; Laberge ML; Villeneuve DJ; Côté GB; Parissenti AM
    Epigenetics; 2008 Sep; 3(5):270-80. PubMed ID: 19001875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation.
    Reed K; Poulin ML; Yan L; Parissenti AM
    Anal Biochem; 2010 Feb; 397(1):96-106. PubMed ID: 19835834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
    Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
    Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing.
    Baker EK; El-Osta A
    Methods Mol Biol; 2010; 596():183-98. PubMed ID: 19949925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression.
    Hatle KM; Neveu W; Dienz O; Rymarchyk S; Barrantes R; Hale S; Farley N; Lounsbury KM; Bond JP; Taatjes D; Rincón M
    Mol Cell Biol; 2007 Apr; 27(8):2952-66. PubMed ID: 17283040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter.
    Sohn BH; Park IY; Lee JJ; Yang SJ; Jang YJ; Park KC; Kim DJ; Lee DC; Sohn HA; Kim TW; Yoo HS; Choi JY; Bae YS; Yeom YI
    Gastroenterology; 2010 May; 138(5):1898-908. PubMed ID: 20038433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Datta Gupta S; Pandya P; Ralhan R
    Clin Biochem; 2010 Mar; 43(4-5):373-9. PubMed ID: 19879256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
    Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
    Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
    Chekhun VF; Kulik GI; Yurchenko OV; Tryndyak VP; Todor IN; Luniv LS; Tregubova NA; Pryzimirska TV; Montgomery B; Rusetskaya NV; Pogribny IP
    Cancer Lett; 2006 Jan; 231(1):87-93. PubMed ID: 16356834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of CpGs as a determinant of transcriptional activation at alternative promoters for transforming growth factor-beta3.
    Archey WB; Sweet MP; Alig GC; Arrick BA
    Cancer Res; 1999 May; 59(10):2292-6. PubMed ID: 10344731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.